Business
Jaguar Health Announces Launch of Mytesi Telehealth Program
This Innovative Program Connects Patients Who May Be Suffering From HIV-Related Diarrhea to a Medical Provider Any Day of the Week and Almost Any Hour of the
About this update from Jaguar Health, Inc.
[{"type":"text","content":"This Innovative Program Connects Patients Who May Be Suffering From HIV-Related Diarrhea to a Medical Provider Any Day of the Week and Almost Any Hour of the Day To Determine if Mytesi® Is Medically Appropriate for ThemSAN FRANCISCO, CA / ACCESSWIRE / May 11, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company's telehealth program went live on May 6, 2022 for Mytesi (crofelemer), Jaguar's FDA-approved antidiarrheal prescription drug indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).\"Telehealth facilitates faster and more expansive patient access to much needed medical care. Telehealth is especially useful for medical problems that patients don't like to discuss, even with their doctors, like diarrhea. The Mytesi telehealth program helps patients who may be suffering from HIV-related diarrhea connect with a medical provider using their mobile phone or any internet-connected device any day of the week and almost any hour of the day,\" said Darlene Horton, M.D., Chief Medical Officer of Napo Pharmaceuticals, Jaguar Health's wholly owned subsidiary. \"Instead of a patient having to wait until their next scheduled medical visit, which could take months, they can receive a medical consultation immediately and be assessed about whether Mytesi is medically appropriate for them.\"The dedicated landing page for the Mytesi telehealth program can be viewed here.About Mytesi®Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medici...